Bronchial Hyperreactivity During Histamine Passive Exposure
NCT ID: NCT01937494
Last Updated: 2015-02-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
13 participants
INTERVENTIONAL
2013-05-31
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inflammatory Processes in the Airway of Asthmatics With Persistent Bronchial Hyperreactivity
NCT00217854
The Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children
NCT01144910
Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness
NCT00605410
Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting
NCT00235911
Comparison of Two Methods of Bronchial Methacholine Provocation
NCT00503659
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Thes test is performed with metacholine or histamine with spirometric documented response to incremental doses.Protection are used to avoid passive exposure of the technicians performing the test, despite the absence of evidence that they could develop a bronchoconstriction if they suffer from BHR.
The purpose of the study is to determine if patients, newly diagnosed with a high level of bronchial hyperreactivity and exposed passively to histamine during a bronchial challenge, are reacting to histamine when placed in the same conditions that the technicians performing these tests.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
asthma patients
patients who show a positive response at the first dos of histamine challenge test will be enrolled
histamine-benzylic alcohol (magistral preparation)
passive exposure to histamine during a bronchial hyperresponsiveness challenge
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
histamine-benzylic alcohol (magistral preparation)
passive exposure to histamine during a bronchial hyperresponsiveness challenge
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Saint Pierre
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marie Bruyneel
CCA, pneumologie
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marie Bruyneel, MD
Role: PRINCIPAL_INVESTIGATOR
CHU ST Pierre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
service de pneumologie, CHU St Pierre
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AK/13-03-34/4235
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.